Buy Rinvoq (Upadacitinib) tablets and oral solution in India at best price

Upadacitinib

Generic Name/API:Upadacitinib
Packaging:Rinvoq extended-release tablets: Each bottle contains 30 tablets or 28 tablets. Rinvoq LQ oral solution: Each bottle contains a labeled volume of 180 mL of clear, colorless to light yellow solution. The bottle is packaged in a carton with one press-in bottle adapter and one 10 mL oral dosing syringe.
Storage:Rinvoq extended-release tablets: Store in the refrigerator at 2°C to 25°C (36°F to 77°F). Rinvoq LQ oral solution: Store between 2°C to 30°C (36°F to 86°F).
Dosage:For dosage information, please check the General Information section.
Strength:Rinvoq extended-release tablets: 15 mg, 30 mg, and 45 mg Rinvoq LQ oral solution: 1 mg/mL
Indication:Upadacitinib is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and in relapsed or refractory follicular lymphoma (FL).

Rinvoq/Rinvoq LQ (Upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the following cases:

  1. Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. 
  2. Treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. 
  3. Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. 
  4. Treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of Rinvoq.
  5. Treatment of adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
  6. Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. 
  7. Treatment of adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. 
  8. Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
  9. Treatment of adults with giant cell arteritis.

Dosage and Strength: 

  • Rinvoq extended-release tablets: 15 mg, 30 mg, and 45 mg 
  • Rinvoq LQ oral solution: 1 mg/mL 

Adverse effects

  • Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis: Upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, and headache. 
  • Giant cell arteritis: Upper respiratory tract infections, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, and nausea. 
  • Atopic dermatitis: Upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increased, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia, and influenza like illness. 
  • Ulcerative colitis: Upper respiratory tract infections, increased blood creatine phosphokinase, acne, neutropenia, elevated liver enzymes, pyrexia, and rash. 
  • Crohn’s disease: Upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster, and headache. 

Storage:

  • Rinvoq extended-release tablets: Store in the refrigerator at 2°C to 25°C (36°F to 77°F). Store in the original bottle in order to protect from moisture.
  • Rinvoq LQ oral solution: Store between 2°C to 30°C (36°F to 86°F). Discard remaining oral solution 60 days after opening the bottle. 
  1. Serious Infections:
    Serious infections, including pneumonia and cellulitis, may occur while taking Rinvoq. Evaluate patients for latent and active tuberculosis (TB) before initiating treatment and monitor for signs and symptoms of TB during therapy, including in patients who previously tested negative for latent TB. Viral reactivation, including herpes virus (e.g., herpes zoster) and hepatitis B virus, may also occur.
  2. Mortality:
    In patients aged 50 years and older with at least one cardiovascular risk factor, treatment with JAK inhibitors has been associated with a higher rate of all-cause mortality, including sudden cardiovascular death.
  3. Malignancy and Lymphoproliferative Disorders:
    Malignancies, including lymphomas, have been reported in patients receiving Rinvoq. Assess the risks and benefits in patients with a history of malignancy (other than successfully treated non-melanoma skin cancer), those who develop malignancy during treatment, and current or former smokers. Cases of non-melanoma skin cancer (NMSC) have also been reported.
  4. Major Adverse Cardiovascular Events (MACE):
    Major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke, may occur in patients treated with Rinvoq.
  5. Thrombosis:
    Thrombotic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, have been observed in patients receiving Rinvoq.
  6. Hypersensitivity Reactions:
    Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with Rinvoq.
  7. Gastrointestinal Perforations:
    Gastrointestinal perforations may occur during treatment with Rinvoq. Monitor patients who are at increased risk, including those with a history of diverticulitis or those receiving concomitant NSAIDs or corticosteroids.
  8. Laboratory Abnormalities
    Treatment with Rinvoq may lead to laboratory abnormalities, including neutropenia, anemia, lymphopenia, and elevated liver enzymes. Increases in lipid parameters, including total cholesterol, LDL cholesterol, and HDL cholesterol, may also occur.

Import Upadacitinib in India through Named Patient Program

FAQ

  • How does Rinvoq work?
  • When is Rinvoq used?
  • What are the ingredients in Rinvoq 45 mg tablets?
  • What dietary restrictions should I make while taking Rinvoq?
  • What is the method of taking Rinvoq tablets and Rinvoq oral solution?
  • What is the cost of Rinvoq (Upadacitinib) online in India?
  • How to Buy Rinvoq/Rinvoq LQ (Upadacitinib) Online in India?
How does Rinvoq work?

When Rinvoq & Rinvoq LQ (Upadacitinib)  inhibits JAK1, the STAT proteins are not activated, inflammatory genes are expressed in small quantities, cytokine signaling decreases and immune response becomes less aggressive. This helps to control inflammation and reduces the harmful effects on other pathways.

When is Rinvoq used?

Rinvoq & Rinvoq LQ (Upadacitinib) is a prescription medicine used to treat several chronic inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis (pJIA), and giant cell arteritis. It is typically prescribed when previous treatments, including TNF blockers or other systemic therapies, have not worked well, were not tolerated, or are not considered suitable by a healthcare provider.

What are the ingredients in Rinvoq 45 mg tablets?

The active ingredient is Upadactinib and the inactive ingredients are colloidal silicon dioxide, hypromellose, iron oxide yellow and iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.

What dietary restrictions should I make while taking Rinvoq?

Avoid food or drink containing grapefruit during treatment with Rinvoq/Rinvoq LQ because eating grapefruit or drinking grapefruit juice may increase the risk of side effects.

What is the method of taking Rinvoq tablets and Rinvoq oral solution?

Take Rinvoq LQ 2 times a day with or without food.

Take Rinvoq tablets 1 time a day with or without food. 

Swallow Rinvoq tablets whole. Do not split, crush, or chew the tablets. Rinvoq LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your healthcare provider.

What is the cost of Rinvoq (Upadacitinib) online in India?

The cost of Rinvoq / Rinvoq LQ is not constant as it’s not approved in India and must be imported. Different parameters such as international currency exchange rates (USD/EUR), import duties and supplier availability determines the final price. For the latest pricing and details, please contact +91 9967979080.

How to Buy Rinvoq/Rinvoq LQ (Upadacitinib) Online in India?

You can directly connect with us at 24/7QualityMeds to buy Rinvoq/Rinvoq LQ (Upadacitinib) online in India at a genuine price. We assist you in importing this medication legally and at the best possible cost. 

"I am very happy with experience of delivery medicine! From start to finish, everything was smooth, professional, and exceeded my expectations. The coordinator was incredibly responsive and friendly, and the product itself best in condition exactly as described. Delivery was fast, packaging was secure, and I felt truly valued as a customer. I'll be coming back and recommending this to friends and family. Once again Thanks for delivering medicine with in 24 hours which help my wife to start treatment on time. "

- Mr. Sanjay More

"I've been using this medicine delivery service for a few months now, and I couldn't be happier. The ordering process is simple and user-friendly, and the delivery is always prompt and reliable. I especially appreciate the timely updates, which help me stay on track with my prescriptions. The coordinator team is responsive and genuinely helpful, always ready to answer questions or resolve any issues. The packaging is secure, and the medicines always arrive in perfect condition. This service has made managing my health so much easier and stress-free. Highly recommended for anyone looking for convenience, reliability, and great customer care! "

- Mr. Nilesh Patankar

"I'm really impressed with the level of service. From placing the order to receiving the medicines, everything is smooth and hassle-free. The coordinator even called several times for updates my package. It's rare to find such thoughtful service these days!"

- Mr. Mohit Vishwakarma

About us

We're a dedicated team of medicine access experts, doctors and pharmacists. We come from all over the world. And we've lost family and friends who could not get the medicine they needed because they lived in the wrong country.

Our mission is to get everyone the right treatment at the right time. Wherever you live. Because you should not suffer or die if a treatment that could help you exists somewhere.

Learn more ›

If you have any questions or need help, we're a phone call away. Our team is available from Monday to Friday between 9 a.m and 6 p.m CET

We usually respond to emails within 24 working hours

Call +919967979080
Email [email protected]

Worldwide Delivery

India

Mumbai, Delhi, Bengaluru, Hyderabad, Chennai, Kolkata, Pune, Ahmedabad, Surat, Jaipur, Lucknow, Noida, Gurugram, Chandigarh, Kochi, Coimbatore, Indore, Bhopal, Visakhapatnam, Vijayawada, Patna, Ranchi, Raipur, Bhubaneswar, Guwahati, Amritsar, Ludhiana, Jodhpur, Dehradun, Srinagar, Jammu, Siliguri, Mysuru, Nagpur, Nashik, Vadodara, Thiruvananthapuram, Cuttack, Warangal, Gangtok, Leh, Kargil, Puducherry, Karaikal, Port Blair, Daman, Silvassa, Kavaratti, Thane, Mangaluru, Nizamabad, Madurai, Rajkot, Udaipur, Kanpur, Kozhikode, Tirupati, Gwalior, Muzaffarpur, Durgapur, Rourkela, Jalandhar, Panipat, Durg-Bhilai, Dhanbad, Silchar, Haldwani, Anantnag, Solan, Vasco da Gama, Pakyong, Agartala, Imphal, Shillong, Dimapur, Aizawl, Itanagar, Yanam, Diu, Dadra.

Asia-Pacific (APAC)

Afghanistan, Australia, Bangladesh, Bhutan, Brunei, Cambodia, China, Christmas Island, Cocos (Keeling) Islands, Cook Islands, Fiji, French Polynesia, Guam, Hong Kong SAR China, Indonesia, Japan, Kazakhstan, Kiribati, Kyrgyzstan, Laos, Macao SAR China, Malaysia, Maldives, Marshall Islands, Micronesia, Mongolia, Myanmar (Burma), Nauru, Nepal, New Caledonia, New Zealand, Niue, Norfolk Island, North Korea, Northern Mariana Islands, Pakistan, Palau, Papua New Guinea, Philippines, Pitcairn Islands, Samoa, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Tajikistan, Thailand, Timor-Leste, Tokelau, Tonga, Turkmenistan, Tuvalu, Uzbekistan, Vanuatu, Vietnam, Wallis & Futuna.

Middle East

Bahrain, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territories, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen.

Europe

Albania, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Faroe Islands, Finland, France, Georgia, Germany, Gibraltar, Greece, Guernsey, Hungary, Iceland, Ireland, Isle of Man, Italy, Jersey, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Moldova, Monaco, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Svalbard & Jan Mayen, Sweden, Switzerland, Ukraine, United Kingdom, Vatican City, Åland Islands.

North America

Antigua & Barbuda, Bahamas, Barbados, Belize, Bermuda, British Virgin Islands, Canada, Cayman Islands, Costa Rica, Cuba, Dominica, Dominican Republic, El Salvador, Greenland, Grenada, Guadeloupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Mexico, Montserrat, Nicaragua, Panama, Puerto Rico, St. Barthélemy, St. Kitts & Nevis, St. Lucia, St. Martin, St. Pierre & Miquelon, St. Vincent & Grenadines, Trinidad & Tobago, Turks & Caicos Islands, United States, U.S. Virgin Islands.

South America

Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela.

Africa

Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo - Brazzaville, Congo - Kinshasa, Côte d'Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Morocco, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, St. Helena, Sudan, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe.

Caribbean Islands

Anguilla, Antigua & Barbuda, Aruba, Bahamas, Barbados, Bermuda, British Virgin Islands, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Montserrat, St. Barthélemy, St. Kitts & Nevis, St. Lucia, St. Martin, St. Pierre & Miquelon, St. Vincent & Grenadines, Trinidad & Tobago, Turks & Caicos Islands, U.S. Virgin Islands.

Disclaimer

All trademarks, logos, brand names, and product names appearing on this website are the property of their respective owners. 247qualitymeds.com does not claim any ownership or affiliation with these trademarks or brands. They are used solely for informational and reference purposes to help users identify products and understand their intended use. The presence of any trademark or brand name on this website does not imply endorsement, sponsorship, or association with 247qualitymeds.com in any form.